Xyphos

Xyphos Biosciences is a private, preclinical-stage biotech company pioneering a novel and adaptable platform for cancer cell therapy. The company's core technology is the convertibleCAR platform, which aims to address key limitations of current CAR-T therapies by enabling control over T-cell activity and targeting multiple antigens. Led by an experienced team with deep expertise in oncology and drug development, Xyphos is working to advance its platform towards clinical development for a variety of cancer indications.

ConvertibleCAR platform: a universal chimeric antigen receptor system designed to create flexible and controllable immune cell therapies, potentially allowing for control over T-cell activity and targeting of multiple antigens via separate adapter molecules.

Xyphos competes in the crowded and fast-moving field of next-generation CAR-T and immune cell therapies. Direct competitors include companies developing switchable, universal, or logic-gated CAR platforms (e.g., Bellicum Pharmaceuticals, Autolus, Cellectis, and numerous private startups). It also competes broadly with developers of TCR therapies, bispecific antibodies, and other immuno-oncology modalities.